In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Jianjun Gao, MD, PhD
Advertisement
Articles by Jianjun Gao, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Oral Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
2
FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
3
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?
4
Novel Adenoid Cystic Carcinoma Drug Earns FDA Breakthrough Therapy Status
5